AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23580740 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of methylphenidate (MPH)
Number of subjects: 30
Study 23580740 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 21385483 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable biopsy needle guide
Number of subjects: 55
Study 21385483 — intervention group
Group type: COMPARATOR
Intervention: Reusable biopsy needle guide
Number of subjects: 55
Study 19670953 — intervention group
Group type: EXPERIMENTAL
Intervention: CPCRS care
Number of subjects: 421
Study 19670953 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 421
Study 17868717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy with a highest dose covering at least 90% of the prostate of 100% or greater
Number of subjects: 568
Study 14962409 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT topographic optic disk measurements
Number of subjects: 439
Study 11347755 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 55
Study 11347755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg ramipril
Number of subjects: 55
Study 11347755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9232976 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted march activity
Number of subjects: 350
Study 9232976 — intervention group
Group type: COMPARATOR
Intervention: Standard recruit training program (running)
Number of subjects: 350
Study 8329830 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)-NH2, 30 micrograms/kg/day
Number of subjects: 60
Study 8329830 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)-NH2, 60 micrograms/kg/day
Number of subjects: 60
Study 8329830 — intervention group
Group type: EXPERIMENTAL
Intervention: GH, 0.1 IU/kg/day
Number of subjects: 60
Study 3540222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (240 mg tablets, twice daily)
Number of subjects: 24
Study 3540222 — intervention group
Group type: COMPARATOR
Intervention: Instant-release verapamil (80 mg tablets, 160 mg twice daily)
Number of subjects: 24
Study 31197867 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 150
Study 31197867 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 150
Study 28222579 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided game (SSG) training intervention for 6 weeks
Number of subjects: 23
Study 28222579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 28222579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both experimental and control groups
Number of subjects: 23
Study 27417317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 mg/m² every 3 weeks)
Number of subjects: 28
Study 27417317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (8.4 mg/m² weekly)
Number of subjects: 28
Study 24813808 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto‐Mixer(®)
Number of subjects: 20
Study 24813808 — intervention group
Group type: COMPARATOR
Intervention: Manual intervention
Number of subjects: 20
Study 22121243 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical and visual absolute effectiveness information
Number of subjects: 638
Study 22121243 — intervention group
Group type: COMPARATOR
Intervention: Standard numerical effectiveness information
Number of subjects: 638
Study 22121243 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term quit rate (1-month)
Number of subjects: 638
Study 22121243 — intervention group
Group type: COMPARATOR
Intervention: Long-term quit rate (12-month)
Number of subjects: 638
Study 20615235 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy adherence intervention
Number of subjects: 0
Study 20615235 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17828094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐intensive broad band electromagnetic radiation of the HFF‐range
Number of subjects: 0
Study 16047528 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice (two 10- to 15-minute counseling sessions)
Number of subjects: 158
Study 16047528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study 12048631 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with hypertonic saline and epinephrine (HSE) injection (n = 14)
Number of subjects: 76
Study 12048631 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with hemoclipping or band ligation (n = 16)
Number of subjects: 76
Study 12048631 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (n = 46)
Number of subjects: 76
Study 10637678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Treatment (specifics not provided)
Number of subjects: 0
Study 10637678 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 7778548 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 10 mg twice daily)
Number of subjects: 734
Study 7778548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 2389694 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg every 6 hours for 6 days)
Number of subjects: 8
Study 2389694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg daily for 7 days)
Number of subjects: 8
Study 2389694 — intervention group
Group type: COMPARATOR
Intervention: Comparison of heart rate response after nadolol withdrawal
Number of subjects: 8
Study 372609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 28
Study 372609 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study 30601976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) monotherapy
Number of subjects: 158
Study 30601976 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC)
Number of subjects: 158
Study 28520484 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 436
Study 28520484 — intervention group
Group type: COMPARATOR
Intervention: Cancer screening comparison condition
Number of subjects: 436
Study 25552279 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised, concentrated added macronutrients parenteral (SCAMP)
Number of subjects: 150
Study 25552279 — intervention group
Group type: COMPARATOR
Intervention: Control PN
Number of subjects: 150
Study 24088534 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus single-dose rifampicin (SDR)
Number of subjects: 20000
Study 24088534 — intervention group
Group type: COMPARATOR
Intervention: BCG only (Control)
Number of subjects: 20000
Study 21418630 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR communication tool
Number of subjects: 0
Study 21418630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient safety card
Number of subjects: 0
Study 21418630 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet with information on common complications post-discharge
Number of subjects: 0
Study 21418630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21418630 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 0
Study 19549054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus active nicotine gum
Number of subjects: 96
Study 19549054 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch plus placebo gum
Number of subjects: 96
Study 17078777 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 24)
Number of subjects: 52
Study 17078777 — intervention group
Group type: COMPARATOR
Intervention: Pre-randomization exercise beliefs
Number of subjects: 52
Study 14745707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:5 dilution of smallpox vaccine
Number of subjects: 674
Study 14745707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10 dilution of smallpox vaccine
Number of subjects: 674
Study 14745707 — intervention group
Group type: COMPARATOR
Intervention: Undiluted smallpox vaccine
Number of subjects: 674
Study 14745707 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects who developed a vesicle after vaccination
Number of subjects: 674
Study 14745707 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger lesion size and fever after vaccination
Number of subjects: 674
Study 11328240 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light therapy (2500 lux)
Number of subjects: 30
Study 11328240 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon bright light therapy (2500 lux)
Number of subjects: 30
Study 9002010 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 9
Study 9002010 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 7924594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy plus chemotherapy
Number of subjects: 0
Study 7924594 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and chemotherapy
Number of subjects: 0
Study 7924594 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU given as continuous infusion
Number of subjects: 0
Study 7924594 — intervention group
Group type: COMPARATOR
Intervention: Preoperative treatment
Number of subjects: 0
Study 3131405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 20 mg
Number of subjects: 8
Study 3131405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 40 mg
Number of subjects: 8
Study 3131405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 60 mg
Number of subjects: 8
Study 3131405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30053455 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly malignant EEG patterns (suppression or burst‐suppression with or without discharges)
Number of subjects: 950
Study 30053455 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign EEG (continuous normal‐voltage background without malignant features)
Number of subjects: 950
Study 26293981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice without sodium lauryl sulfate (SLS) for 8 weeks
Number of subjects: 120
Study 26293981 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice with sodium lauryl sulfate (SLS) for 8 weeks
Number of subjects: 120
Study 23838904 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of S‐1/cisplatin (SC)
Number of subjects: 83
Study 23838904 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of S‐1/cisplatin (SC)
Number of subjects: 83
Study 23838904 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of paclitaxel/cisplatin (PC)
Number of subjects: 83
Study 23838904 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of paclitaxel/cisplatin (PC)
Number of subjects: 83
Study 23838904 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 22623075 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal
Number of subjects: 196
Study 22623075 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 196
Study 20392316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 500
Study 20392316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 18039339 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 20
Study 18039339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14709254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS) pulpotomy
Number of subjects: 50
Study 14709254 — intervention group
Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 50
Study 11306777 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia and neglect as assessed by the NIHSS in acute stroke patients
Number of subjects: 0
Study 11306777 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical aphasia or neglect
Number of subjects: 0
Study 11306777 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS measures of aphasia and neglect
Number of subjects: 0
Study 9340953 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral gold and methotrexate
Number of subjects: 24
Study 9340953 — intervention group
Group type: COMPARATOR
Intervention: Baseline (T0)
Number of subjects: 24
Study 9340953 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 (after 36 months)
Number of subjects: 24
Study 7880658 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid (lactated Ringer's) 15 ml kg‐1
Number of subjects: 20
Study 7880658 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid (hydroxyethyl starch) 7.5 ml kg‐1
Number of subjects: 20
Study 3284218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.3 mg/kg body weight)
Number of subjects: 20
Study 3284218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31891544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled disposable tray containing potassium nitrate and fluoride
Number of subjects: 78
Study 31891544 — intervention group
Group type: COMPARATOR
Intervention: Conventional tray containing potassium nitrate and fluoride
Number of subjects: 78
Study 29105107 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 70 lotion sunscreen applied at a dosage of 2 mg cm‐2 on half of the face
Number of subjects: 24
Study 29105107 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 70 spray sunscreen applied at a dosage of 2 mg cm‐2 on one of the forearms
Number of subjects: 24
Study 29105107 — intervention group
Group type: COMPARATOR
Intervention: Untreated control sites (no sunscreen)
Number of subjects: 24
Study 27522535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis (3.56‐5.60% THC)
Number of subjects: 42
Study 27522535 — intervention group
Group type: COMPARATOR
Intervention: Inactive cannabis (0.00% THC)
Number of subjects: 42
Study 26720884 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light-emitting toothbrushes (B-LETBs)
Number of subjects: 0
Study 26720884 — intervention group
Group type: COMPARATOR
Intervention: Standard toothbrushes (Control)
Number of subjects: 0
Study 23559082 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d vitamin D3
Number of subjects: 192
Study 23559082 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 192
Study 23559082 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D3
Number of subjects: 192
Study 23559082 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety measurements
Number of subjects: 192
Study 20599042 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (5, 15, and 45 mg/kg, administered orally 3 times a day for 6 months)
Number of subjects: 48
Study 20599042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 months)
Number of subjects: 48
Study 18349182 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40
Study 18349182 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 40
Study 18349182 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA) and Laryngeal Tube (LT)
Number of subjects: 40
Study 17142216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 112
Study 17142216 — intervention group
Group type: COMPARATOR
Intervention: Bedtime insulin
Number of subjects: 112
Study 12685385 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice a day for 7 days
Number of subjects: 80
Study 12685385 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg in a single morning dose for 7 days
Number of subjects: 80
Study 12685385 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice a day for 7 days and further 3 weeks 20 mg twice a day
Number of subjects: 80
Study 11153337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of bladder volume
Number of subjects: 153
Study 11153337 — intervention group
Group type: COMPARATOR
Intervention: Standard catheterization
Number of subjects: 153
Study 8957368 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic talc insufflation under general anesthesia (n = 28)
Number of subjects: 57
Study 8957368 — intervention group
Group type: COMPARATOR
Intervention: Talc slurry by the bedside (n = 29)
Number of subjects: 57
Study 1583760 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 232
Study 1583760 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 232
Study 1583760 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and EPC
Number of subjects: 232
Study 3888393 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (50 mg at bedtime for the first week, then 75 mg or 100 mg as needed for the remainder of the six-week trial)
Number of subjects: 10
Study 3888393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31521551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (packs of crushed ice applied to the knee with mild compression)
Number of subjects: 60
Study 31521551 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (packs filled with sand)
Number of subjects: 60
Study 29507952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-component health care professional HPV vaccine communication intervention
Number of subjects: 43132
Study 29507952 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 43132
Study 27154767 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based parenting program (5-month program followed by two 1-month boosters)
Number of subjects: 1076
Study 27154767 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based parenting program
Number of subjects: 1076
Study 25452854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention group (ILG)
Number of subjects: 294
Study 25452854 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 294
Study 22364690 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (1/10 of the daily furosemide dose divided into twice daily dosing)
Number of subjects: 7
Study 22364690 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (mean dose 5.13 mg/kg/day)
Number of subjects: 7
Study 20966667 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot femoral nerve block (SSFNB) with concurrent PCA opioids
Number of subjects: 1016
Study 20966667 — intervention group
Group type: COMPARATOR
Intervention: Single-shot femoral nerve block (SSFNB) plus sciatic nerve block
Number of subjects: 1016
Study 20966667 — intervention group
Group type: COMPARATOR
Intervention: Single-shot femoral nerve block (SSFNB) plus continuous FNB
Number of subjects: 1016
Study 17683554 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment in the weeks near death
Number of subjects: 115
Study 17683554 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment in the prospective analysis
Number of subjects: 115
Study 17683554 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment in the retrospective analysis
Number of subjects: 115
Study 12629471 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n=7)
Number of subjects: 14
Study 12629471 — intervention group
Group type: COMPARATOR
Intervention: Control (n=7)
Number of subjects: 14
Study 11206210 — intervention group
Group type: EXPERIMENTAL
Intervention: few-fixed condition
Number of subjects: 0
Study 11206210 — intervention group
Group type: EXPERIMENTAL
Intervention: many-fixed condition
Number of subjects: 0
Study 11206210 — intervention group
Group type: EXPERIMENTAL
Intervention: critical items
Number of subjects: 0
Study 11206210 — intervention group
Group type: EXPERIMENTAL
Intervention: list items
Number of subjects: 0
Study 9377612 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 762
Study 9377612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 762
Study 1588374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HIDAC) 3 g/m2 ara-C infused over 3 hours at 12-hour intervals on days 1, 3, and 5
Number of subjects: 176
Study 1588374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HIDAC)
Number of subjects: 176
Study 1588374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model parameters: creatinine greater than or equal to 1.2 mg/dL, age greater than or equal to 40 years, and alkaline phosphatase (AP) greater than or equal to 3 x normal
Number of subjects: 176
Study 31476786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal administration of betamethasone
Number of subjects: 115
Study 31510777 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 12
Study 31510777 — intervention group
Group type: COMPARATOR
Intervention: No carvedilol therapy (control)
Number of subjects: 12
Study 28353650 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention providing strategies for increasing physical activity
Number of subjects: 82
Study 28353650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messaging intervention)
Number of subjects: 82
Study 26525720 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal cells (arm A)
Number of subjects: 269
Study 26525720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐invasive breast cancer cells (arm B)
Number of subjects: 269
Study 23966615 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler measurements in severe growth restriction (umbilical artery pulsatility index, MCA pulsatility index, ductus venosus pulsatility index)
Number of subjects: 51
Study 23966615 — intervention group
Group type: COMPARATOR
Intervention: Umbilical artery pulsatility index in normally grown fetuses
Number of subjects: 51
Study 21435907 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plate
Number of subjects: 60
Study 21435907 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 60
Study 19746764 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer applied to the right side of the face
Number of subjects: 102